SCHEMBL31367528

SCHEMBL31367528

CC(=O)c1ccc(-c2cc(-c3ccc(C(C)=O)cc3)c3nc(-c4ccccc4)cn3c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 7/20 0.55
ALDH1A2 O94788 4/20 0.55
ALDH1A1 P00352 3/20 0.55
MAPT P10636 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
DHODH Q02127 1/20 0.49
TMIGD3 P0DMS9 7/20 0.48
ADORA3 P0DMS8 1/20 0.47
ADORA1 P30542 2/20 0.43
ADORA2A P29274 1/20 0.43
SLC2A1 P11166 1/20 0.43
SGK1 O00141 1/20 0.43
MAOB P27338 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31367417 0.94 ALDH1A3 (0.55) ALDH1A3ALDH1A2ALDH1A1MAPTSMN1; SMN2
SCHEMBL31367433 0.94 ALDH1A3 (0.55) ALDH1A3ALDH1A2ALDH1A1MAPTSMN1; SMN2
SCHEMBL31367546 0.94 ALDH1A3 (0.50) ALDH1A3ALDH1A2ALDH1A1MAPTSMN1; SMN2
SCHEMBL31367516 0.94 ALDH1A3 (0.55) ALDH1A3ALDH1A2ALDH1A1MAPTSMN1; SMN2
SCHEMBL31367536 0.91 ALDH1A3 (0.52) ALDH1A3ALDH1A2ALDH1A1MAPTSMN1; SMN2
SCHEMBL31367511 0.90 HSD17B1 (0.50) ALDH1A3ALDH1A2ALDH1A1MAPTSMN1; SMN2
SCHEMBL31367620 0.88 ALDH1A3 (0.53) ALDH1A3ALDH1A2ALDH1A1MAPTSMN1; SMN2
SCHEMBL31367461 0.88 ALDH1A3 (0.52) ALDH1A3ALDH1A2ALDH1A1DHODHTMIGD3
SCHEMBL31367450 0.88 ALDH1A3 (0.52) ALDH1A3ALDH1A2ALDH1A1DHODHTMIGD3
SCHEMBL31367521 0.88 ALDH1A3 (0.52) ALDH1A3ALDH1A2ALDH1A1DHODHTMIGD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735442-A1 IMIDAZO[1,2-alpha]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS Theranib Inc. (CA) 2026-05-06 EP claimed
US-20250011322-A1 MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A THERANIB INC. (CA) 2025-01-09 US claimed
EP-4735442-A1 IMIDAZO[1,2-alpha]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS Theranib Inc. (CA) 2026-05-06 EP disclosed
US-20250011322-A1 MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A THERANIB INC. (CA) 2025-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011322-A1 MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A ALDH2, ALDH3A1, ALDH1A1 ALDH1A3 8/4885ALDH1A2 4/4885ALDH1A1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.